Lung Cancer
- Hormone Therapy Not Linked to Lung Cancer in Postmenopausal Women
- Osimertinib and Platinum Chemo Produces Unprecedented Results in NSCLC
- Artificial Intelligence Can Predict Cancer Survival Using Data From a Single Consultation
- Pembrolizumab Improves 5-Year PFS, OS in Metastatic NSCLC
- Cancer Patients May Be Treated With Drugs That Provide No Benefit
- Chemotherapy Improves Outcomes in EFGR-Mutated NSCLC With Brain Metastases
- Most Quality Metrics for Cancer Screening Tests Are Not Supported by Evidence
- Positive 5-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
- Pembrolizumab Doubles 5-Year OS in Advanced NSCLC, but OS Remains Low
- Sublobar Resection Not Inferior to Lobar Resection for T1aN0 NSCLC
- Lung Cancer Screening Based on Personal Risk Is Cost-Effective
- Targeted Therapies for Non-Small Cell Lung Cancer Underused in Patients on Medicaid
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
